GEMINI Results of HIV 2 Drug Regimen Investor & Analyst Update

On Tuesday, 24 July 2018, GSK hosted an investor conference call following the presentation of the full set of scientific and clinical data on GSK’s 2 drug regimen of dolutegravir plus lamiviudine (GEMINI studies) in treatment naïve HIV patients at the 22nd International AIDS Conference.

The call was hosted by David Redfern, GSK Chief of Strategy and Chairman of ViiV Healthcare, Deborah Waterhouse, CEO of ViiV Healthcare, John Pottage, Chief Scientific & Medical Officer of ViiV Healthcare, and Kimberly Smith, VP Global Research & Medical Strategy of ViiV Healthcare.